Biosimulation Market Is Expected to Reach $4.9 billion by 2030, Grow at a CAGR Of 20.1% during Forecast Period 2023 To 2030 | Data By Contrive Datum Insights Pvt Ltd.
10 mai 2023 00h00 HE
|
Contrive Datum Insights Pvt Ltd
Farmington, May 10, 2023 (GLOBE NEWSWIRE) -- The Global Biosimulation Market Was Valued At $1.3 billion In 2022 And Is Expected To Expand $4.9 billion By 2030 at a CAGR Of 20.1% From 2022 To 2030....
Certara Reports First Quarter 2023 Financial Results
08 mai 2023 16h15 HE
|
Certara
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. ...
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
27 avr. 2023 08h00 HE
|
Certara
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
10 avr. 2023 16h30 HE
|
Certara
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of...
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
07 mars 2023 08h00 HE
|
Certara
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new...
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
01 mars 2023 16h16 HE
|
Certara
PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022...
Certara Announces Transition Plan for Chief Financial Officer
01 mars 2023 16h15 HE
|
Certara
PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1,...
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
01 févr. 2023 16h30 HE
|
Certara
PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and...
Global Biosimulation Market had crossed a worth of US$ 2.6 Bn in 2021, with a predicted CAGR of 21.5%; the market is estimated to reach revenue of US$ 20.9 Bn by year 2032-end | FMI
19 déc. 2022 21h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
DUBAI, United Arab Emirates, Dec. 19, 2022 (GLOBE NEWSWIRE) -- The Global Biosimulation Market was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 20.9 Bn by 2032, finds Future Market...
Global Biosimulation Market Report 2022: Market to Grow by $5.5+ Billion by 2028
16 déc. 2022 07h43 HE
|
Research and Markets
Dublin, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The "Global Biosimulation Market (2022 Edition) - Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User,...